Study Finds Good Adherence, Low ADE Rates With Oral DMTs

The multiple sclerosis (MS) therapeutic class boasts more than 20 disease modifying therapies (DMTs) that have various routes of administration. A recent study of oral therapies to treat relapsing-remitting MS (RRMS) found that they are well tolerated, have high adherence rates and have low rates of adverse events.

AllianceRx Walgreens Prime conducted the research in conjunction with Duquesne University School of Pharmacy. The study was presented at the Academy of Managed Care Pharmacy’s AMCP 2021 virtual conference in April.

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_article_Anthem_Launches_Voluntary.jpg
September 9

Anthem Launches Voluntary Oncology Dose Reduction Program

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_Pharmacy_article_Home_Infusion_Policies.jpg
September 9

Legislation Seeks to Change Medicare Home Infusion Policies

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/Specialty_Pharmacy_article_Specialty_Trend.jpg
September 9

Specialty Trend Increase Slows; Biosimilars Are Having Impact

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today